Ozempic is a prescription medication approved for adults with type 2 diabetes. It helps control blood sugar, and it also carries FDA approvals for reducing cardiovascular risk and slowing kidney disease progression in people with type 2 diabetes. While it’s become widely known as a weight loss drug, Ozempic itself is not approved for weight management. A separate, higher-dose version of the same medication (Wegovy) carries that approval.
Type 2 Diabetes and Blood Sugar Control
The primary reason doctors prescribe Ozempic is to lower blood sugar in adults with type 2 diabetes, alongside diet and exercise. It was first approved by the FDA in 2017 for this purpose. In clinical trials, patients taking Ozempic saw their A1C levels drop by 0.6 to 1.6 percentage points compared to other treatments, a meaningful reduction that can shift someone from poorly controlled diabetes into a healthier range.
Ozempic works by mimicking a natural gut hormone called GLP-1. When your blood sugar rises after eating, this hormone signals your pancreas to release more insulin. Ozempic amplifies that signal. It also dials back glucagon, a hormone that tells your liver to dump stored sugar into your bloodstream. On top of that, it slows how fast food leaves your stomach, which prevents the sharp blood sugar spikes that happen after meals. You inject it once a week, and the maximum dose for diabetes is 2 mg per week.
Heart Disease Risk Reduction
Ozempic’s second approved use is reducing the risk of major cardiovascular events in adults who have both type 2 diabetes and established heart disease. That means heart attacks, strokes, and cardiovascular death. In combined data from two large trials, semaglutide (the active ingredient in Ozempic) reduced the risk of a first major cardiovascular event by 24% compared to placebo in older adults with type 2 diabetes and obesity. This isn’t a side benefit. It’s a distinct FDA-approved indication, and for people with diabetes who already have heart disease, it can be a significant reason to choose this medication over alternatives.
Kidney Disease Protection
The newest approved use, added after a major trial called FLOW, targets adults with type 2 diabetes and chronic kidney disease. In that study, patients on semaglutide had an 18.7% rate of major kidney events (including kidney failure, the need for dialysis, or death from kidney or cardiovascular causes) compared to 23.2% in the placebo group. That translates to a 24% lower risk. Semaglutide also slowed the rate at which kidney function declined over time. Cardiovascular death dropped by 29%, and overall mortality dropped by 20% compared to placebo. For people with diabetes whose kidneys are already showing damage, this is a meaningful layer of protection.
Weight Loss: Why It’s Complicated
Ozempic is not FDA-approved for weight loss, but it’s frequently prescribed off-label for that purpose. The reason is straightforward: the same drug, semaglutide, is the active ingredient in Wegovy, which is approved for weight management. Both are weekly injections. The key difference is dosing. Ozempic maxes out at 2 mg per week, while Wegovy can go up to 7.2 mg per week for patients who need additional weight reduction.
Semaglutide-based medications can produce average weight loss of 15 to 20% of starting body weight, far more than older weight loss drugs achieved. About half of patients lose 20% or more, with some losing up to 30%. The weight loss comes from the same mechanisms that help with blood sugar: slowed stomach emptying makes you feel full longer, and the drug acts on appetite centers in the brain to reduce hunger and cravings.
The reason many people end up on Ozempic rather than Wegovy for weight loss often comes down to insurance coverage and drug availability. But if weight management is the primary goal, Wegovy is the version specifically studied and approved for it.
Common Side Effects
Digestive issues are the most common side effects, and they’re not rare. In a two-year study, 82% of patients on semaglutide experienced gastrointestinal symptoms compared to 54% on placebo. The typical complaints are nausea, stomach pain, bloating, constipation, diarrhea, and vomiting. Most of these are mild to moderate, and they tend to improve after the first 20 weeks of use. The dose is usually increased gradually over several weeks specifically to minimize these effects.
Who Should Not Take Ozempic
Ozempic carries a boxed warning about thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors at doses relevant to humans. Whether this risk applies to people hasn’t been determined, but the FDA treats it seriously. Ozempic is contraindicated if you or a close family member has a history of medullary thyroid carcinoma, or if you have a condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated if you’ve had a serious allergic reaction to semaglutide.
Symptoms to be aware of include a lump or swelling in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness. These could indicate thyroid changes that need evaluation.
Ozempic vs. Wegovy
Since both contain semaglutide, the confusion between them is understandable. Here’s how they differ:
- Ozempic is approved for type 2 diabetes, cardiovascular risk reduction in diabetic patients, and kidney disease protection in diabetic patients. Maximum dose: 2 mg per week.
- Wegovy is approved for weight management in adults and adolescents 12 and older with obesity (or overweight with related health conditions), cardiovascular risk reduction in adults with established heart disease and excess weight, and treatment of a liver condition called MASH with moderate to advanced scarring. Maximum dose: 7.2 mg per week.
If your doctor is prescribing semaglutide primarily for blood sugar control, you’ll get Ozempic. If the main goal is weight loss or you don’t have type 2 diabetes, Wegovy is the appropriate version. In practice, the line blurs because many people with type 2 diabetes also benefit from the weight loss, and both conditions improve with the same drug.